Saccharin
(Synonyms: 糖精) 目录号 : GC39505
Saccharin (Benzoic sulfimide, O-Sulfobenzimide, O-Benzoic sulfimide, Saccharimide) is an artificial sweetener with effectively no food energy.
Cas No.:81-07-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Saccharin (Benzoic sulfimide, O-Sulfobenzimide, O-Benzoic sulfimide, Saccharimide) is an artificial sweetener with effectively no food energy.
| Cas No. | 81-07-2 | SDF | |
| 别名 | 糖精 | ||
| Canonical SMILES | O=C(C1=C2C=CC=C1)NS2(=O)=O | ||
| 分子式 | C7H5NO3S | 分子量 | 183.18 |
| 溶解度 | DMSO : 36mg/mL | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.4591 mL | 27.2956 mL | 54.5911 mL |
| 5 mM | 1.0918 mL | 5.4591 mL | 10.9182 mL |
| 10 mM | 0.5459 mL | 2.7296 mL | 5.4591 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
High-dose Saccharin supplementation does not induce gut microbiota changes or glucose intolerance in healthy humans and mice
Microbiome 2021 Jan 12;9(1):11.PMID:33431052DOI:10.1186/s40168-020-00976-w.
Background: Non-caloric artificial sweeteners (NCAS) are widely used as a substitute for dietary sugars to control body weight or glycemia. Paradoxically, some interventional studies in humans and rodents have shown unfavorable changes in glucose homeostasis in response to NCAS consumption. The causative mechanisms are largely unknown, but adverse changes in gut microbiota have been proposed to mediate these effects. These findings have raised concerns about NCAS safety and called into question their broad use, but further physiological and dietary considerations must be first addressed before these results are generalized. We also reasoned that, since NCAS are bona fide ligands for sweet taste receptors (STRs) expressed in the intestine, some metabolic effects associated with NCAS use could be attributed to a common mechanism involving the host. Results: We conducted a double-blind, placebo-controlled, parallel arm study exploring the effects of pure Saccharin compound on gut microbiota and glucose tolerance in healthy men and women. Participants were randomized to placebo, Saccharin, lactisole (STR inhibitor), or Saccharin with lactisole administered in capsules twice daily to achieve the maximum acceptable daily intake for 2 weeks. In parallel, we performed a 10-week study administering pure Saccharin at a high dose in the drinking water of chow-fed mice with genetic ablation of STRs (T1R2-KO) and wild-type (WT) littermate controls. In humans and mice, none of the interventions affected glucose or hormonal responses to an oral glucose tolerance test (OGTT) or glucose absorption in mice. Similarly, pure Saccharin supplementation did not alter microbial diversity or composition at any taxonomic level in humans and mice alike. No treatment effects were also noted in readouts of microbial activity such as fecal metabolites or short-chain fatty acids (SCFA). However, compared to WT, T1R2-KO mice were protected from age-dependent increases in fecal SCFA and the development of glucose intolerance. Conclusions: Short-term Saccharin consumption at maximum acceptable levels is not sufficient to alter gut microbiota or induce glucose intolerance in apparently healthy humans and mice. Trial registration: Trial registration number NCT03032640 , registered on January 26, 2017. Video abstract.
Saccharin
Diabetes Care 1989 Jan;12(1):74-80.PMID:2653753DOI:10.2337/diacare.12.1.74.
Saccharin, a nonnutritive sweetener discovered in 1879, has been the subject of controversy concerning its effect on public health on several occasions during this century. Over this period, the substance has come to be regarded as a useful commodity in the dietary management of diabetes mellitus. We review the historical and scientific background on the subject and propose a new approach in making public-health decisions on unique foods that serve a special dietary purpose.
The Saccharin controversy
Diabetes Care 1978 Jul-Aug;1(4):211-22.PMID:400131DOI:10.2337/diacare.1.4.211.
Saccharin and its salts are the most extensively consumed artificial sweeteners in the United States today. The current controversy about the risks of their use to human health has surfaced from research findings that report an increased incidence of cancer, primarily of the urinary bladder, in certain animal species and man chronically exposed to these agents. The April 1977 proposal by the Food and Drug Administration to restrict use of Saccharin was based on these investigations. The intense public response against any ban has led to Congressional deliberations over the fate of Saccharin during the present moratorium and information-gathering period. Since diabetic patients are among the principal users of this compound, it appears timely to review the evidence for and against its carcinogenic potential.
Saccharin: a toxicological and historical perspective
Toxicology 1983 Jul-Aug;27(3-4):179-256.PMID:6353664DOI:10.1016/0300-483x(83)90021-5.
Saccharin, first synthesized in 1879, eventually became popular as an inexpensive substitute for sugar, particularly as a non-caloric sweetner. The dispute concerning the safety of Saccharin for human consumption is almost as old as Saccharin itself. In this article, the history concerning the uses of Saccharin and the accompanying controversy are reviewed. In addition, the spectrum of toxicological and epidemiological studies to which Saccharin has been subjected are also examined. While the toxicological data indicate that Saccharin is probably the agent solely responsible for the bladder tumors observed in second generation male rats, the epidemiological studies provide, at best, an equivocal relationship between the consumption of Saccharin and bladder cancer. A benefit-risk evaluation for Saccharin showed few, if any documentable benefits from the use of Saccharin and much genuine uncertainty concerning the potential risks for ingestion by man. This element of genuine uncertainty as to the extent of human risk posed to man is the crux of Saccharin's past and its foreseeable future.
Saccharin's aversive taste in rats: evidence and implications
Neurosci Biobehav Rev 1993 Winter;17(4):359-72.PMID:8309647DOI:10.1016/s0149-7634(05)80113-7.
In most biobehavioral research using rats as subjects, Saccharin is viewed as a "sugar substitute"--sweet, palatable, and conveniently lacking in calories. This characterization has merit: Saccharin seems to share some sensory, affective, and motivating properties with sugars. This paper focuses on Saccharin's lesser known, aversive properties. Evidence of Saccharin's distinctive taste in rats is reviewed, followed by discussion of several modulating variables. Procedures that influence rats' responses to Saccharin and their measurement are summarized, and the argument is advanced that Saccharin can be used to study the relationship of taste and ingestion to learning, stress, and emotional processes in rats and humans.